小RNA
特发性肺纤维化
下调和上调
肺纤维化
纤维化
医学
背景(考古学)
癌症研究
肺
免疫学
病理
生物
内科学
遗传学
基因
古生物学
作者
Julien Guiot,Monique Henket,Claire Remacle,Maureen Cambier,Ingrid Struman,Marie Winandy,Catherine Moermans,Édouard Louis,Michel Malaise,Clio Ribbens,Renaud Louis,Makon‐Sébastien Njock
标识
DOI:10.1186/s12931-023-02413-6
摘要
Pulmonary fibrosis is an emerging complication of SARS-CoV-2 infection. In this study, we speculate that patients with COVID-19 and idiopathic pulmonary fibrosis (IPF) may share aberrant expressed microRNAs (miRNAs) associated to the progression of lung fibrosis.To identify miRNAs presenting similar alteration in COVID-19 and IPF, and describe their impact on fibrogenesis.A systematic review of the literature published between 2010 and January 2022 (PROSPERO, CRD42022341016) was conducted using the key words (COVID-19 OR SARS-CoV-2) AND (microRNA OR miRNA) or (idiopathic pulmonary fibrosis OR IPF) AND (microRNA OR miRNA) in Title/Abstract.Of the 1988 references considered, 70 original articles were appropriate for data extraction: 27 studies focused on miRNAs in COVID-19, and 43 on miRNAs in IPF. 34 miRNAs were overlapping in COVID-19 and IPF, 7 miRNAs presenting an upregulation (miR-19a-3p, miR-200c-3p, miR-21-5p, miR-145-5p, miR-199a-5p, miR-23b and miR-424) and 9 miRNAs a downregulation (miR-17-5p, miR-20a-5p, miR-92a-3p, miR-141-3p, miR-16-5p, miR-142-5p, miR-486-5p, miR-708-3p and miR-150-5p).Several studies reported elevated levels of profibrotic miRNAs in COVID-19 context. In addition, the balance of antifibrotic miRNAs responsible of the modulation of fibrotic processes is impaired in COVID-19. This evidence suggests that the deregulation of fibrotic-related miRNAs participates in the development of fibrotic lesions in the lung of post-COVID-19 patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI